Analysis
Analysis
Pelthos buys a gene therapy, and the market blinks
Pelthos agreed on Oct 30 to buy Castle Creek with a $57.5M preferred PIPE converting at $19.67. Its shares closed at $9.40 that day.
The biotech IR desk. Where money meets opportunities. Not investment advice.
Summary. On October 30, 2026 Pelthos Therapeutics (PTHS) agreed to merge with Castle Creek Biosciences, whose lead asset is D-Fi, a gene-modified cell therapy for dystrophic epidermolysis bullosa (DEB). Castle Creek holders get 5.2M Pelthos shares, about 32.5% on a fully diluted basis, plus up to 5.8M more shares and $300M in milestones. Investors including Ligand agreed to buy $57.5M of Series B convertible preferred, convertible at $19.67. Pelthos shares closed at $9.40 that day, down from $16.54 on October 29.
Shareholders rarely mark a company down by more than 40% in a day for buying something. Pelthos's did. The terms explain part of it: Pelthos, which sells three approved dermatology products, is swapping a third of itself for a late-stage rare-disease programme whose Phase 3 study is still to be continued, and is borrowing more to do it.
The merger terms
The 8-K sets out the price. Castle Creek's owners receive 5.2M Pelthos shares at closing, with 10% held in escrow for two years. If D-Fi wins FDA approval by March 31, 2036, they receive up to 5.8M more shares, cut by 5% for each full quarter after March 31, 2031. Cash milestones total $300M: $50M for a clinical milestone by June 30, 2029, $50M on first US sale, and $50M, $75M and $75M when trailing sales first reach $100M, $250M and $500M. They also keep 80% of the net proceeds of any priority review voucher.
The press release says closing is expected by the end of the first quarter of 2027. Scott Plesha stays chief executive and Peter Greenleaf becomes executive chair. The board grows to 10, with two Castle Creek designees. Oppenheimer gave Pelthos's board a fairness opinion. Pelthos shareholder approval of the share issuance is to come by written consent rather than a meeting, and is a condition of closing.
The money
The PIPE comprises 57,500 Series B preferred shares at $1,000 stated value plus warrants on 496,951 common shares, for about $57.5M, paid partly in cash and partly by handing over Castle Creek bridge notes. A specified "Option Buyer" may add up to $26.6M by November 14, and other Castle Creek holders up to $1.5M, for a maximum of $80.0M. The filing names Ligand Pharmaceuticals, Nomis Bay and Marshman Fund Trust II among the buyers. Proceeds go first to repay Castle Creek debt.
Pelthos also amended its loan with Horizon Technology Finance. Horizon funded $10.0M more, taking term loans to $40.0M, at prime plus 3.75% with a 6.75% prime floor, so at least 10.5%. Horizon receives warrants on 37,292 shares at $16.09.
Deals reviewed
- October 30, 2026: Series B convertible preferred PIPE with warrants, $57.5M committed (up to $80.0M). 8-K
- October 30, 2026: Amended venture loan with Horizon, $10.0M added, $40.0M outstanding, with warrants. 8-K
Analysis: the case for caution
Our view is that the deal is defensible strategically and costly in ways the headline understates.
Start with what is unusual. The Series B converts at $19.67, roughly 19% above the $16.54 close before the announcement and more than twice the $9.40 close after it. In our view a conversion price that far above market is unusual, so the Series B certificate of designation filed with the 8-K deserves close reading. The 8-K says the terms include a "Voluntary Adjustment Right" letting Pelthos, with consent of the required Series B holders and subject to NYSE American rules, lower the conversion price.
Next, the balance sheet. The second-quarter 10-Q shows $24.2M of cash at June 30, a six-month net loss of $48.5M and $20.8M of cash used in operations. Much of the new money services Castle Creek's debts, and Pelthos takes on a Phase 3 programme and a $40.0M floating-rate loan.
Then governance. On October 28, two days before signing, the compensation committee raised Mr Plesha's base salary from $500,000 to $550,000 and his target bonus from 50% to 60% of salary. On October 30 his severance terms were widened to include a prorated bonus based on actual performance. The 8-K gives no reason for either change. It discloses these facts; it does not link them to the merger, and neither do we. Shareholders are entitled to ask the board to explain the timing.
The case for the deal is real: DEB is a severe disease, D-Fi has orphan drug designation according to the Pelthos and Castle Creek release, and Pelthos already sells into dermatologists. The contingent structure also shifts much of the price onto success.
What to watch
The Form S-4 and information statement, whether the Option Buyer takes its $26.6M by November 14, HSR clearance and the timing of D-Fi's continued Phase 3.
FAQ
What is Pelthos buying? Castle Creek Biosciences and its DEB gene therapy D-Fi, per the October 30 8-K.
How is the deal financed? A $57.5M Series B preferred PIPE, up to $80.0M, and $10.0M more Horizon debt.
Who are the PIPE investors? The filing names Ligand, Nomis Bay and Marshman Fund Trust II, among others.
Is this investment advice? No. This is analysis of public filings.
Sources: Pelthos Therapeutics SEC filings and press release as linked. Share prices are closing prices for October 29 and 30, 2026. Not investment advice.
Sources
Disclosures
- Every figure carries the as-of date of its source.
- This analysis was drafted with AI tools from the company's own filings, FDA documents and trial registries. Every number is checked against its source and an editor reviews the piece before it is published.
- Our method and conflicts policy: aibio.space/disclosures/
aibio.space and its owner hold no position in any stock covered in this report.
As of , aibio.space has received no compensation from, and has no paid relationship with, the company covered.
Investor Chat
Loading posts…
aibio